You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Targeted Therapies 101

  • Authors: Zofia Piotrowska, MD; Dara L. Aisner, MD, PhD; Helena Yu, MD; Angel Qin, MD; Tara Plues, CNP
  • CME / ABIM MOC / CE Released: 3/31/2023
  • Valid for credit through: 3/31/2024
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, nurses/nurse practitioners (NPs), physician assistants (PAs), and pharmacists.

The goal of this activity is for the learner to be better able to individualize care for patients with non-small cell lung cancer (NSCLC) and molecular alterations as part of the interprofessional team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating targeted therapies for patients with NSCLC
  • Have greater competence related to
    • Utilizing diagnostic methodologies to identify molecular alterations in patients with NSCLC
    • Personalizing therapy for patients with NSCLC and molecular alterations
    • Mitigating treatment‐related adverse events (TRAEs) in patients receiving targeted therapy for NSCLC
  • Demonstrate greater confidence in their ability to
    • Communicate treatment considerations across an interprofessional care team with patients with NSCLC and molecular alterations


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Zofia Piotrowska, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Zofia Piotrowska, MD, has the following relevant financial relationships:
    Consultant or advisor for: Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo, Inc.; Janssen; Jazz Pharmaceuticals; Lilly; Takeda
    Research funding from: AbbVie, Inc.; AstraZeneca; Blueprint Medicines; Cullinan Oncology; Daiichi Sankyo, Inc.; GlaxoSmithKline; Janssen; Novartis; Spectrum Pharmaceuticals; Takeda; Tesaro, Inc.

  • Dara L. Aisner, MD, PhD

    Professor of Pathology
    Medical Director, Colorado Molecular Correlates Laboratory (CMOCO)
    University of Colorado
    Aurora, Colorado

    Disclosures

    Dara L. Aisner, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca; Bristol Myers Squibb Company; Genentech; LOXO Oncology; Sanofi Genzyme; Takeda
    Research funding from: Genentech

  • Helena Yu, MD

    Associate Attending
    Section Head, Molecular Targets in Lung Cancer
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Helena Yu, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cullinan Oncology; Daiichi Sankyo, Inc.; Janssen; Taiho Pharmaceutical Co., Ltd.
    Research funding from: AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cullinan Oncology; Daiichi Sankyo, Inc.; Erasca; Janssen; Novartis; Pfizer, Inc.

  • Angel Qin, MD

    Clinical Assistant Professor
    Medical Oncology, Internal Medicine
    University of Michigan Health
    Brighton, Michigan

    Disclosures

    Angel Qin, MD, has the following relevant financial relationships:
    Research funding from: Ascentage Pharma; AstraZeneca; Clovis Oncology; Merck; Xencor, Inc.

  • Tara Plues, CNP

    Hematology and Medical Oncology
    The Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Tara Plues, CNP, has no relevant financial relationships.

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-081-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Targeted Therapies 101

Authors: Zofia Piotrowska, MD; Dara L. Aisner, MD, PhD; Helena Yu, MD; Angel Qin, MD; Tara Plues, CNPFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/31/2023

Valid for credit through: 3/31/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Best Practices for Molecular Testing in Advanced NSCLC and Decoding NGS Reports

How much do you know about optimal molecular testing methods for patients with advanced NSCLC?
Dara L. Aisner, MD, PhD

What Do We Do When Osimertinib Stops Working for Classic EGFR Mutations?

Do you know how to best manage your patients with mNSCLC and EGFR mutations that progress after osimertinib?
Helena Yu, MD

Next-Generation ALK Inhibitors and the Management of ALK-Positive NSCLC

Get the latest information on ALK inhibitors for mNSCLC.
Angel Qin, MD

Tips and Tricks for Management of TKI-Related Toxicities

Learn optimal management strategies for TKI-related toxicities.
Tara Plues, CNP
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print